BioStem Acquires BioTissue’s Surgical And Wound Care Business, Expands Wound Healing Portfolio

BioStem Technologies announced that it has completed an asset purchase agreement to acquire the surgical and wound care business of BioTissue Holdings, expanding its footprint in the advanced wound healing market. The deal brings well-known placental-derived product lines Neox® and Clarix® into BioStem’s portfolio, along with the commercial infrastructure supporting those brands, including a nationwide sales network and major group purchasing organization (GPO) contracts.

BioTissue, long recognized for its regenerative innovations in ophthalmology, developed its surgical and wound care portfolio for applications beyond eye care. By integrating these assets, BioStem significantly enlarges its in-house commercial organization and strengthens its presence across both inpatient and outpatient hospital settings. The company said the transaction positions it to accelerate entry into acute wound care and soft-tissue repair while reinforcing its leadership in chronic wound management.

“This acquisition is a natural strategic fit that underscores BioStem’s commitment to leading the field of advanced wound care. It provides an immediate foothold in hospital-based applications and expands our technology portfolio with an additional platform designed to optimize the preservation of both placental and umbilical tissue allografts,” said Jason Matuszewski, CEO and Chairman of BioStem. “This acquired technology opens meaningful entry into high-value adjacent market segments, from acute surgical wounds to burns and soft-tissue repair, while creating synergies that enhance our entire product suite and diversify our revenue streams. BioTissue’s broad and innovative surgical portfolio, robust pipeline, and highly skilled sales force, combined with BioStem’s reach and operational strengths, uniquely position us to address patient needs across the spectrum of acute and chronic wound care. I am excited to welcome the impressive team of BioTissue employees to further our mission of delivering the most advanced wound healing technologies in the world.”

Financially, BioStem paid about $15 million in upfront cash, with the possibility of additional payments tied to regulatory and commercial milestones. These include up to $10 million upon achieving 510(k) clearance for a new product and up to $15 million in future royalty-based milestones. The transaction was approved by the boards of both companies.

The acquired business generated roughly $29 million in revenue in 2025 and is expected to deliver growth and positive EBITDA for BioStem in 2026. Following the closing, BioStem reported cash and restricted cash of approximately $16 million, supporting its plans to scale operations and integrate the newly acquired assets.